Phenoxyacetamide structural analogues of Chlodantane and ADK-918
Patent disclosure · 2018
- What the patent describes
- Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
- Reported evidence
- The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.
Analogue 1 recovery · 15.1 g, 85% yield · Manufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Reported patent results
Reported findings
The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.
Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
Population or model Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Analogue 1 recovery | 15.1 g, 85% yield | Manufacturing result for the newly claimed analogue, not Chlodantane or ADK-918 |
| Analogue 2 recovery | 80% yield; melting interval 94.5–95.0°C | A different new analogue; analytical characterization |
Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Platform context. The claimed phenoxyacetamides are described as structural analogues of ADK-910 and ADK-918, rather than claims to those reference compounds themselves.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2660654C1 ↗ · 2018-07-09
- Earliest priority / filing
- 2017-06-09 / 2017-06-09
- Original applicant / assignee
- Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 62815866 · family publications are related filings, not independent studies.
Original title, inventors and related publications
N-(adamantan-2-yl)- and n-[(adamantan-1-yl)methyl]- derivatives of 2-(4-allyl-2-methoxyphenoxy)acetic acid amide, which are potential synthetic adaptogens of emergency action
Inventors: Иван Александрович Новаков; Лейла Липпаритовна Брунилина; Андрей Александрович Вернигора; Максим Борисович Навроцкий; Борис Семёнович Орлинсон; Александр Сергеевич Яблоков.
Study limitations and source details
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Source details
Source identity and selected abstract or text passages checked; complete methods not appraised.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
Author unconfirmed. Phenoxyacetamide structural analogues of Chlodantane and ADK-918 RU2660654C1; Volgograd State Technical University
Related compounds
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.
ADK-918
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.